Amneal Pharmaceuticals Inc. (AMRX)
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings
Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio.
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Balaji Prasad - Barclays Bank Leszek Sulewski - Truist Securities Chris Schott - JPMorgan Operator Hello, everyone and thank you for your patience. The Amneal Pharmaceuticals Third Quarter 2024 Earnings Call will begin shortly.
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
